{"organizations": [], "uuid": "6e9d491de8381736be8d6bca0b55f6e8ac9b2629", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-redhill-biopharma-announces-final/brief-redhill-biopharma-announces-final-results-from-phase-ii-study-with-bekinda-for-ibs-d-idUSFWN1PB13C", "country": "US", "domain_rank": 408, "title": "BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.713, "site_type": "news", "published": "2018-01-16T21:11:00.000+02:00", "replies_count": 0, "uuid": "6e9d491de8381736be8d6bca0b55f6e8ac9b2629"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-redhill-biopharma-announces-final/brief-redhill-biopharma-announces-final-results-from-phase-ii-study-with-bekinda-for-ibs-d-idUSFWN1PB13C", "ord_in_thread": 0, "title": "BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "redhill biopharma ltd", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "bekinda", "sentiment": "none"}, {"name": "redhill biopharma", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Redhill Biopharma Ltd:\n* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDAÂ® FOR IBS-D\n* REDHILL BIOPHARMA - INDEPENDENT REVIEW & ANALYSIS OF FINAL RESULTS CONFIRMED THAT PHASE II STUDY WITH BEKINDA 12 MG SUCCESSFULLY MET PRIMARY ENDPOINT\n* REDHILL BIOPHARMA - PLANS TO MEET WITH FDA IN H1 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T21:11:00.000+02:00", "crawled": "2018-01-17T20:07:31.015+02:00", "highlightTitle": ""}